Tempest Therapeutics, Inc.
Filings
| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-236/23/26 | New | $4,056,552 | $4,056,552 | Equity Only | 06b | SEC linkSEC |
| 2026-04-034/3/26 | New | $1,999,539 | $1,999,539 | Equity Only | 06b | SEC linkSEC |
| 2022-05-115/11/22 | New | $15,000,000 | $15,000,000 | Equity Only | 06b | SEC linkSEC |
| 2013-03-283/28/13 | New | $34,999,920 | $34,999,920 | Equity Only | 06 | SEC linkSEC |
| 2012-08-148/14/12 | Amended | $4,936,547 | $859,138 | Equity Only | 06 | SEC linkSEC |
| 2012-08-038/3/12 | Amended | $4,077,409 | $441,463 | Equity Only | 06 | SEC linkSEC |
| 2012-07-207/20/12 | Amended | $3,635,946 | $2,232,324 | Equity Only | 06 | SEC linkSEC |
| 2012-07-057/5/12 | New | $1,403,622 | $1,403,622 | Equity Only | 06 | SEC linkSEC |
| 2012-04-094/9/12 | New | $37,238,097 | $37,238,097 | Equity Only | 06 | SEC linkSEC |
Directors and Executives (Current and Past)
| Name | Role |
|---|---|
| Richard Aldrich | Director |
| Matthew Angel | Director, Executive |
| Christopher A. Bleck | Executive |
| Stephen Brady | Director |
| Jeff Capello | Director |
| Scott Chappel | Executive |
| Michelle Dipp | Director, Executive |
| Thomas W. Dubensky | Director, Executive |
| Michael Flanagan | Executive |
| Stephen Kraus | Director |
| Alison Lawton | Executive |
| Nicholas Maestas | Executive |
| Thomas Malley | Director |
| Geoffrey Nichol | Director |
| Christine Pellizzari | Director |
| Michael Raab | Director |
| William Drake Richey | Director |
| Ronit Simantov | Director |
| John Simon | Director |
| Harald Stock | Director |
| Jonathan Tilly | Director |
| Justin Trojanowski | Executive |
| Christoph Westphal | Director |
| Thomas Woiwode | Director |
| John David Yee | Director |
Industry: Biotechnology (See others in industry)
Address:
2000 Sierra Point Parkway, Suite 400
Brisbane, CA, 94005
Phone: 415-798-8589
Brisbane, CA, 94005
Phone: 415-798-8589